A Phase I/II Open–Label study to Assess the Safety, Tolerability and Preliminary Efficacy of FP-1201 (Recombinant Human Interferon Beta) in the treatment of patients with Acute Lung Injury and Acute Respiratory Distress Syndrome.

Faron Pharmaceuticals Limited0 个研究点开始时间: 2008年2月29日最近更新: 2012年3月19日

试验速览

暂无简介。

•Adult male or female patients with ALI/ARDS confirmed by the combination of the following diagnostic criteria:
•An initiating clinical condition (e.g. sepsis, pneumonia, aspiration pneumonia, pancreatitis etc.)
•Acute onset
•Bilateral infiltrates documented by chest radiograph at end-aspiratory position
•The absence of clinical evidence of left atrial hypertension
•ALI: Pa02 /Fi02 ratio = 300 in a stable state after the patient has adapted to standardised ventilation.(Within the UK this equates to <40 kPa)
•ARDS: Pa02 /Fi02 = 200 in a stable state after the patient has adapted to standardised ventilation.(Within the UK this equates to <26.7 kPa)
•Provision of signed written informed consent from the patient or patients legally authorized representative
•Age greater than or equal to 18.
•Initiation of study drug within 48 hours of the diagnosis of ALI/ARDS
•All patients at entry are required to be receiving mechanical ventilatory support
•Only patients who are considered suitable for active life support should be enrolled in the study.
•No clinical evidence of left atrial hypertension that would explain the pulmonary infiltrates; if measured the pulmonary arterial wedge pressure should be less than or equal to 18mmHg
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Patients with burns
•Women known to be pregnant, lactating or having a positive or indeterminate pregnancy test.
•Patients with significant COPD requiring ongoing treatment e.g. chronic use of oxygen or ventilatory support at home prior to admission.
•Patients with primary lung cancer or the presence of secondary metastases in the lungs.
•Patients requiring treatment for congestive heart failure
•Patients receiving renal dialysis therapy for chronic renal failure.
•Patients taking immumodulatory therapy or oral steroids on admission.
•Prior use of interferon.
•Inability to maintain blood pressure to ensure adequate end organ perfusion. It should be noted that the use of plasma colloids or vasopressor agents is allowed to achieve the maintenance of blood pressure.
•Current participation in another experimental treatment protocol.

发起方

Faron Pharmaceuticals Limited